Siemens Healthineers: The Buyback That Keeps Running While the Market Weighs the Margin Math

Siemens Healthineers lifts EPS guidance to €2.35–€2.45, but shares remain 11% below 2025 start. Analysts split on valuation amid diagnostics headwinds.

The arithmetic at Siemens Healthineers is getting harder to ignore. The medical technology group has lifted its earnings-per-share guidance for the current fiscal year to €2.35–€2.45, up from a previous range of €2.20–€2.30, yet the shares still sit 11 percent below where they started 2025. That gap between management's confidence and the market's caution is now the central tension driving the stock.

The numbers behind the debate are straightforward enough. In the third fiscal quarter, which closed at the end of July, the company generated revenue of €5.76 billion and profit of €676 million. On the buyback front, Siemens Healthineers acquired another 50,000 of its own shares between August 10 and 16, bringing the cumulative total since the program began on June 1 to 2,824,371 shares. The steady pace of repurchases suggests management sees value in its own equity, even as external observers remain split on what the stock is actually worth.

A Rebound With a Ceiling

The share price has clawed back ground recently, closing Wednesday at €40.14 after a 2.0 percent daily gain. Over the past 30 sessions, the stock has advanced roughly 15 percent, a notable recovery from the 52-week low of €32.84 touched in May. Yet context matters: the equity remains about 19 percent below its 52-week high of €49.78 from last October, and on a twelve-month view it is still down 17 percent.

That partial recovery has unfolded against a mixed operational backdrop. Mid-August brought news that the company had trimmed its revenue growth forecast for fiscal 2026 to 3.5–4 percent. Reuters attributed the downgrade to weakness in the diagnostics division, citing procurement policy shifts in China and the ongoing migration to a new laboratory platform as the principal drags.

Analysts Draw Different Lines

The sell-side response to the revised outlook has been anything but uniform. JPMorgan emerged as the clear bull, reiterating an "Overweight" rating in early August and lifting its price target to €57.40 — a level that implies substantial upside from current trading. At the other end of the spectrum, Berenberg had downgraded the stock to "Hold" back in July following what it judged to be mixed results, while Bernstein trimmed its price target in early August even as it maintained an "Outperform" stance, flagging headwinds to earnings per share.

UBS has kept a neutral posture with a €38 price objective, and Deutsche Bank moved its target modestly higher from €38 to €39 while holding the rating at "Hold." The wide dispersion in targets — from the low €30s to the mid-€50s — tells its own story about how little consensus exists on the trajectory of the diagnostics business.

The Spin-Off Clock Ticks Forward

One factor that has helped steady the share price is progress on the corporate structure. Reuters reported in early August that Siemens had reached an agreement with German tax authorities on a tax-free structure for the planned distribution of Healthineers shares to Siemens shareholders. That clarification removes a meaningful layer of uncertainty from the spin-off process and has likely contributed to the firmer tone in the stock.

The separation still carries execution risk, however. Until the timeline and final structure are locked in, questions about the future capital structure and degree of independence will linger — a consideration that can keep institutional investors on the sidelines.

What Would Make the Rally Stick

The decisive variable is whether the margin improvement behind the raised profit guidance is structural or merely a function of one-off gains. If the coming quarterly reports confirm that cost discipline is translating into durable operating leverage, the skepticism weighing on the stock could begin to lift. If, instead, the improvement fades — or proves to be driven more by expense cuts than genuine growth — the shares could slide back toward the more cautious price targets on the Street.

The 200-day moving average sits at €39.11, not far from the current price, which means the stock is essentially testing a technical level that could either confirm the recovery or expose its fragility. The next earnings report will be the first real test of whether the raised guidance has substance behind it.

Until then, Siemens Healthineers remains a stock caught between two narratives: one of a management team that sees a turnaround taking hold, and another of analysts who want proof before they pay up for it. The buyback program continues to provide a floor of sorts, but it is unlikely to be the factor that decides the direction from here.